Vinflunine for the treatment of breast cancer - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Expert Opinion on Pharmacotherapy Year : 2016

Vinflunine for the treatment of breast cancer


Introduction: Breast cancer is the most frequently diagnosed cancer and the highest cause of cancer mortality in females worldwide. The development of drugs improving overall survival in late-stage metastatic breast cancer remains a challenge. Vinflunine is the most recently developed drug in the vinca alkaloid class. Its arrival has been eagerly awaited for treatment of solid tumors, and in particular, for metastatic breast cancer. Areas covered: The pharmacological features of vinflunine are described. Its clinical development as monotherapy or in combination in metastatic breast cancer is detailed. A literature search on the topic was conducted through PubMed, clinical trials and the proceedings of the main cancer congresses. Expert opinion: The overall results from phase III studies, and in particular those that combined vinflunine with capecitabine, have been less favorable. The combination's effectiveness was at best moderate compared with other drugs which also target metastatic breast cancer, and complicated by significant hematological and gastrointestinal adverse effects. Its use in advanced metastatic breast cancer cannot currently be recommended.


Embargoed file
Embargoed file
Visibility date is undetermined

Dates and versions

inserm-01822667 , version 1 (25-06-2018)



Carole Gourmelon, Heloise Bourien, Paule Augereau, Anne Patsouris, Jean-Sébastien Frenel, et al.. Vinflunine for the treatment of breast cancer. Expert Opinion on Pharmacotherapy, 2016, 17 (13), pp.1817 - 1823. ⟨10.1080/14656566.2016.1217991⟩. ⟨inserm-01822667⟩
73 View
1 Download



Gmail Facebook X LinkedIn More